Research Signal – Source date 2022-03-01
A 2022 systematic review and meta-analysis found a sharp difference in reported responses to PD-1/PD-L1 inhibitor monotherapy for endometrial cancer. The pooled objective response rate was 45% among tumors with deficient mismatch repair (dMMR), compared with 4% among tumors with proficient mismatch repair (pMMR). Mismatch repair is a system cells use to correct certain DNA-copying errors; these labels describe whether that repair system is deficient or proficient in a tumor.
The gap is striking, but it needs careful reading. These are pooled results from studies of a treatment class, not a personal forecast or a comparison proving which treatment is best. They suggest that tumor repair status may help distinguish groups with different reported outcomes, while leaving open how reliably that distinction can guide an individual decision.
Two ways to describe tumor outcomes
The review reported an overall objective response rate (ORR) of 29%. ORR counts patients whose tumors met the studies’ criteria for shrinking in response to treatment. It does not include every patient whose disease may have stopped worsening or remained stable.
A second measure, disease-control rate (DCR), includes objective responses and disease that was stable under the study definitions. The pooled DCR was 48% overall. By mismatch repair group, it was 58% for dMMR tumors and 21% for pMMR tumors. The difference between the groups therefore appeared in both measures, though response and disease control describe distinct outcomes.
These percentages summarize patients across the studies included in the analysis. They cannot tell a reader what will happen to one person. The abstract does not report how many studies or patients contributed to the estimates, or how much results varied across studies. Other features of a person’s cancer and care also matter, but these figures alone do not quantify them.
Benefit is only part of treatment experience
The review reported adverse events in 65% of patients, with grade-three-or-higher events in 14%. In this reporting system, grade indicates severity; grade three or higher refers to more serious events. The figures show why response rates cannot describe the full experience of treatment. The supplied results do not break adverse-event rates out by mismatch repair group, so they do not show whether the safety profile differed between pMMR and dMMR patients.
The analysis focused on PD-1/PD-L1 inhibitor monotherapy. Its pooled figures do not establish that this approach is preferable to a particular alternative, or that either tumor group should receive it. The response split is evidence about outcomes reported across the reviewed studies, not a treatment-selection rule.
A useful clue, with questions still open
The review’s central contribution is the size and direction of the reported difference: response and disease-control rates were higher in the deficient mismatch repair group. The abstract does not establish why the groups differed biologically. It also does not show whether mismatch repair status alone can reliably predict benefit for a particular patient.
Those limits matter because a group average and an individual outlook answer different questions. The pooled results make tumor classification a plausible part of a treatment conversation; they do not settle the conversation. Comparisons with relevant treatment alternatives, clearer patient-level results and a fuller account of uncertainty would be needed to judge how useful the split is for choosing care.
What this could change
For someone with recurrent endometrial cancer, a more dependable link between mismatch repair results and treatment outcomes could help make discussions with a clinician more specific: whether checkpoint inhibitor monotherapy looks promising for that person’s tumor, and how its possible benefit fits alongside other options. The tumor classifications and drugs already existed; what could change is the strength of evidence for using the classification in decisions.
A nearer milestone would be a study reporting response and adverse-event outcomes separately for pMMR and dMMR groups, alongside relevant treatment comparators. Such evidence could test whether the pooled split holds up and make the trade-offs easier to assess. Only if that distinction proves reliable in patient-level and comparative evidence could it support more confident treatment choices.
Key Sources
- Primary source: PD-1/PD-L1 Inhibitors Monotherapy for the Treatment of Endometrial Cancer: Meta-Analysis and Systematic Review.
DOI or Journal Page · Review or Meta-Analysis · 2022-03-01
Keep exploring